Detalhe da pesquisa
1.
Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models.
Br J Cancer
; 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38600326
2.
Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.
Histopathology
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38651302
3.
Profiling of Tumour-Infiltrating Lymphocytes and Tumour-Associated Macrophages in Ovarian Epithelial Cancer-Relation to Tumour Characteristics and Impact on Prognosis.
Int J Mol Sci
; 25(8)2024 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38674108
4.
Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective.
Br J Cancer
; 128(3): 474-477, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36434156
5.
Pathology of neoadjuvant therapy and immunotherapy testing for breast cancer.
Histopathology
; 82(1): 170-188, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36482270
6.
Characterization of the Immune Microenvironment in Inflammatory Breast Cancer Using Multiplex Immunofluorescence.
Pathobiology
; 90(1): 31-43, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-35705026
7.
Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects.
Br J Cancer
; 126(8): 1125-1139, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34893761
8.
The presentation, management and outcome of patients with ductal carcinoma in situ (DCIS) with microinvasion (invasion ≤1 mm in size)-results from the UK Sloane Project.
Br J Cancer
; 127(12): 2125-2132, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36224403
9.
The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry-equivocal invasive breast cancer.
Histopathology
; 81(4): 511-519, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35879836
10.
Dataset for pathology reporting of ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions: recommendations from the International Collaboration on Cancer Reporting (ICCR).
Histopathology
; 81(4): 467-476, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35869801
11.
Receptor Status after Neoadjuvant Therapy of Breast Cancer: Significance and Implications.
Pathobiology
; 89(5): 297-308, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35636403
12.
Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension.
Lancet Oncol
; 22(10): e435-e445, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34592193
13.
Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project.
Br J Cancer
; 124(5): 1009-1017, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33199800
14.
Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases.
Br J Cancer
; 124(11): 1836-1842, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33762723
15.
Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer.
Mod Pathol
; 34(7): 1271-1281, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33526875
16.
Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study.
Mod Pathol
; 34(12): 2130-2140, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34218258
17.
Morphological and molecular changes following neoadjuvant endocrine therapy of oestrogen receptor-positive breast cancer: implications for clinical practice.
Histopathology
; 79(1): 47-56, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33423290
18.
The CD151-midkine pathway regulates the immune microenvironment in inflammatory breast cancer.
J Pathol
; 251(1): 63-73, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32129471
19.
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Lancet Oncol
; 21(10): 1296-1308, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32919527
20.
Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement.
Br J Cancer
; 122(4): 473-482, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31907370